Ratings AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
67.75 USD -0.75% Intraday chart for AstraZeneca PLC +2.36% +0.59%

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • The company's enterprise value to sales, at 3.6 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+0.59% 210B -
+33.46% 701B
C+
+26.24% 571B
B
+0.93% 381B
C+
+21.03% 334B
B-
+17.51% 319B
C+
+2.95% 210B
B-
-6.05% 201B
A+
-3.61% 157B
C+
-1.28% 153B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes